{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:51:07Z","timestamp":1778694667272,"version":"3.51.4"},"reference-count":28,"publisher":"Baskent University","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.6002\/ect.mesot2021.o15","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T02:37:05Z","timestamp":1649299025000},"page":"39-45","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic Ablative Body Radiotherapy as a Bridge to Liver Transplant for Hepatocellular Carcinoma: Preliminary Results of Ba\u015fkent University Experience"],"prefix":"10.6002","volume":"20","author":[{"given":"Guler","family":"Yavas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru Hatice","family":"Ayvazoglu Soy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Boyvat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Haberal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology. 2021;73 Suppl 1:158-191. doi:10.1002\/hep.31327","DOI":"10.1002\/hep.31327"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157(1):54-64. doi:10.1053\/j.gastro.2019.02.049","DOI":"10.1053\/j.gastro.2019.02.049"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Haberal M, Akdur A, Moray G, et al. Expanded criteria for hepatocellular carcinoma in liver transplant. In: Hakim N, Haberal M, Maluf D (Eds). Transplantation Surgery. 2nd ed. Springer Nature Switzerland; 2021:249-254.","DOI":"10.1007\/978-3-030-55244-2_16"},{"key":"ref3","unstructured":"4. Haberal M, Emiroglu R, Karakayali H, et al. Expanded criteria for hepatocellular carcinoma and liver transplantation. Int Surg. 2007;92(2):110-115."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ma KW, Cheung TT. Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2017;4:1-9. doi:10.2147\/JHC.S96085","DOI":"10.2147\/JHC.S96085"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699. doi:10.1056\/NEJM199603143341104","DOI":"10.1056\/NEJM199603143341104"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35-43. doi:10.1016\/S1470-2045(08)70284-5","DOI":"10.1016\/S1470-2045(08)70284-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys. 2012;83(3):895-900. doi:10.1016\/j.ijrobp.2011.08.032","DOI":"10.1016\/j.ijrobp.2011.08.032"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology. 2000;31(4):1019-1021. doi:10.1053\/he.2000.6959","DOI":"10.1053\/he.2000.6959"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237-1248. doi:10.1016\/0360-3016(94)00418-K","DOI":"10.1016\/0360-3016(94)00418-K"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452-459. doi:10.1200\/JCO.2015.61.4925","DOI":"10.1200\/JCO.2015.61.4925"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Yoon SM, Lim YS, Park MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One. 2013;8(11):e79854. doi:10.1371\/journal.pone.0079854","DOI":"10.1371\/journal.pone.0079854"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Mazzola R, Fersino S, Alongi P, et al. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by (18)F-FDG-PET\/CT. Br J Radiol. 2018;91(1088):20180058. doi:10.1259\/bjr.20180058","DOI":"10.1259\/bjr.20180058"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Wang YF, Dai YH, Lin CS, et al. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol. 2021;16(1):15. doi:10.1186\/s13014-020-01739-5","DOI":"10.1186\/s13014-020-01739-5"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Moore A, Cohen-Naftaly M, Tobar A, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017;12(1):163. doi:10.1186\/s13014-017-0899-4","DOI":"10.1186\/s13014-017-0899-4"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Mannina EM, Cardenes HR, Lasley FD, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol Biol Phys. 2017;97(5):931-938. doi:10.1016\/j.ijrobp.2016.12.036","DOI":"10.1016\/j.ijrobp.2016.12.036"},{"key":"ref16","unstructured":"17. Gresswell S, Tobillo R, Hasan S, et al. Stereotactic body radiotherapy used as a bridge to liver transplant in patients with hepatocellular carcinoma and Child-Pugh score >\/=8 cirrhosis. J Radiosurg SBRT. 2018;5(4):261-267."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92-99. doi:10.1016\/j.jhep.2017.02.022","DOI":"10.1016\/j.jhep.2017.02.022"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. doi:10.1055\/s-0030-1247132","DOI":"10.1055\/s-0030-1247132"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Guarneri A, Franco P, Romagnoli R, et al. Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. Radiol Med. 2016;121(11):873-881. doi:10.1007\/s11547-016-0670-1","DOI":"10.1007\/s11547-016-0670-1"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18(8):949-954. doi:10.1002\/lt.23439","DOI":"10.1002\/lt.23439"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Sandroussi C, Dawson LA, Lee M, et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int. 2010;23(3):299-306. doi:10.1111\/j.1432-2277.2009.00980.x","DOI":"10.1111\/j.1432-2277.2009.00980.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e447-453. doi:10.1016\/j.ijrobp.2011.04.011","DOI":"10.1016\/j.ijrobp.2011.04.011"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631-1639. doi:10.1200\/JCO.2012.44.1659","DOI":"10.1200\/JCO.2012.44.1659"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424-5431. doi:10.1002\/cncr.27533","DOI":"10.1002\/cncr.27533"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94(6):1747-1752. doi:10.1002\/cncr.10407","DOI":"10.1002\/cncr.10407"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78(4):1073-1080. doi:10.1016\/j.ijrobp.2009.09.009","DOI":"10.1016\/j.ijrobp.2009.09.009"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Jung J, Yoon SM, Kim SY, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013;8:249. doi:10.1186\/1748-717X-8-249","DOI":"10.1186\/1748-717X-8-249"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:12:33Z","timestamp":1649304753000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/supplement\/2022\/20\/3\/1\/39\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2021.o15","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}